PharmaEssentia to Present Preclinical Data on PEC2001 and PEC3001 Solid Tumor Immunotherapy Candidates at SITC 2026
PharmaEssentia Innovation Research Center (PIRC), a subsidiary of PharmaEssentia Corporation (TWSE: 6446), has announced two poster presentations featuring preclinical research from its internal drug development portfolio at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting. The meeting is scheduled to take place November 4–8, 2026, in Phoenix, Arizona, bringing together researchers, clinicians, and industry professionals to discuss advances in cancer immunotherapy.
The two presentations will highlight the development of PEC2001 and PEC3001, investigational candidates designed to address different mechanisms involved in the immune response to solid tumors. The research reflects PharmaEssentia’s efforts to expand its scientific and therapeutic focus beyond myeloproliferative neoplasms (MPNs) into broader oncology opportunities through its internal research and development capabilities.
The company’s discovery programs build on its expertise in PEGylated cytokines, checkpoint receptor biology, and cytokine engineering. By combining these areas of research, PharmaEssentia aims to develop biologic therapies that modulate the immune system and potentially improve its ability to recognize and attack cancer cells.
PEC2001 is being investigated as a dual antagonist targeting leukocyte immunoglobulin-like receptor B1 (LILRB1) and LILRB2, two receptors associated with the regulation of myeloid immune cell activity. The candidate is designed to reprogram myeloid immunity and enhance antitumor responses in solid tumors.
PEC3001, meanwhile, is a programmed death protein 1 (PD-1)-targeted immunocytokine incorporating interleukin-2 (IL-2) activity directed toward the IL-2 receptor alpha (IL-2Rα). Its development strategy is intended to concentrate immune-stimulating activity around PD-1-expressing cells while limiting broader systemic immune activation.
Together, the two programs represent different approaches to cancer immunotherapy. PEC2001 focuses on modulating myeloid checkpoint pathways, while PEC3001 seeks to combine targeted immune engagement with cytokine activity. The company plans to use the preclinical findings to inform the continued development of its solid tumor pipeline.
“These presentations reflect the strength of our discovery engine and our ambition to build a pipeline with MPN as its core and broader opportunities beyond,” said Lih-Ling Lin, Ph.D., Chief Scientific Officer at PharmaEssentia. “We look forward to moving our solid tumor pipeline candidates into IND-enabling and Phase 1 studies.”
PEC2001 Targets LILRB1 and LILRB2 to Modulate Myeloid Immunity
The first presentation will focus on PEC2001, an investigational dual LILRB1/LILRB2 antagonist designed to influence myeloid immune responses and strengthen antitumor activity.
Titled “PEC2001, a differentiated dual LILRB1/LILRB2 antagonist, reprograms myeloid immunity and enhances anti-tumor activity,” the poster will present preclinical findings supporting the candidate’s mechanism of action, immune activity, and potential application in solid tumors.
- Poster number: 411
- Presenter: Ali Sepahi, Ph.D., PharmaEssentia
- Presentation date: Friday, November 6, 2026
- Conference: SITC 41st Annual Meeting, Phoenix, Arizona
LILRB1 and LILRB2 are inhibitory immune receptors involved in regulating the activity of myeloid cells, a broad group of immune cells that includes monocytes, macrophages, and certain antigen-presenting cells. These cells can influence the development and progression of cancer by affecting immune surveillance, inflammation, and interactions within the tumor microenvironment.
In some cancers, inhibitory signaling pathways can contribute to an environment that limits effective antitumor immune responses. Tumors may exploit such regulatory mechanisms to reduce immune cell activation or create conditions that favor cancer growth and persistence.
Targeting inhibitory receptors involved in these processes is therefore an area of interest in immuno-oncology research. By interfering with selected checkpoint pathways, investigators aim to alter the behavior of immune cells and improve their capacity to participate in tumor control.
PEC2001 has been developed to inhibit both LILRB1 and LILRB2. According to PharmaEssentia, its differentiated inhibition mechanism demonstrated improved selectivity and enhanced antitumor immune activation in preclinical research.
The company also reported strong preclinical efficacy, supporting further evaluation of PEC2001 as a potential myeloid checkpoint inhibitor for solid tumors.
The dual-targeting approach is intended to address immune regulation through two related receptors rather than focusing on a single checkpoint. Its potential value will depend on the extent to which the candidate can modify immune cell activity, produce meaningful antitumor effects, and maintain an acceptable safety profile.
The reported preclinical findings provide an early basis for further investigation, although they do not establish clinical benefit in patients. Additional research will be needed to determine how PEC2001 performs in more advanced development settings and whether its mechanism translates into therapeutic activity in human cancers.
Potential Role in Solid Tumor Immunotherapy
Solid tumors can create complex biological environments that suppress immune responses and limit the effectiveness of certain immunotherapies. These environments may involve interactions among cancer cells, immune cells, signaling molecules, and other components of the tumor microenvironment.
Myeloid cells are particularly relevant to this process because they can perform different functions depending on the signals they receive. Some myeloid cell populations can support immune activation, while others may contribute to immunosuppression and tumor progression.
By targeting LILRB1 and LILRB2, PEC2001 is being developed to alter inhibitory signaling that may constrain antitumor immune activity.
PharmaEssentia’s preclinical findings suggest that the candidate could offer a differentiated approach to modulating these pathways. However, the poster’s reported results should be interpreted within the context of early-stage research. Further studies will be necessary to characterize its activity across tumor types, establish the durability of its effects, and evaluate its potential safety and tolerability.
The research may also help guide future investigations into whether PEC2001 could be used alone or in combination with other cancer treatments. Such possibilities would require additional experimental evidence and, ultimately, clinical evaluation.
For PharmaEssentia, the program represents an opportunity to apply its internal discovery capabilities to immune checkpoint biology beyond its established focus on hematologic diseases.
PEC3001 Combines PD-1 Targeting With IL-2 Immunocytokine Activity
The second poster will examine PEC3001, an investigational immunocytokine designed to combine PD-1-targeted delivery with IL-2 activity involving the IL-2 receptor alpha subunit.
The presentation is titled “Pre-clinical characterization of PEC3001, a PD-1 targeted IL-2Rα-active IL-2 immunocytokine with potent anti-tumor activity and a favorable safety profile.”
- Poster number: 897
- Presenter: John Huck, Ph.D., PharmaEssentia
- Presentation date: Friday, November 6, 2026
- Conference: SITC 41st Annual Meeting, Phoenix, Arizona
PEC3001 is designed to engage PD-1 while delivering cytokine-mediated immune stimulation. The approach seeks to combine targeted immune modulation with the biological activity of IL-2, a signaling protein involved in the growth, survival, and function of immune cells.
PD-1 is an immune checkpoint receptor expressed on certain immune cells, including activated T cells. Its interaction with relevant ligands can reduce immune cell activity and contribute to mechanisms through which tumors evade immune surveillance.
PD-1-directed therapies have become an important component of cancer immunotherapy. However, the effectiveness of checkpoint inhibition can vary among patients and cancer types, creating continued interest in approaches that combine checkpoint targeting with additional immune-stimulating mechanisms.
IL-2 has long been studied for its ability to influence T-cell activity and other immune responses. Its therapeutic development, however, has been complicated by the challenge of achieving useful immune stimulation while managing unwanted effects associated with systemic exposure.
Immunocytokines are designed to combine a targeting component with a cytokine or cytokine-related function. The objective is to direct immune-modulating activity toward selected cells or tissues while potentially reducing effects in other parts of the body.
PEC3001 applies this general strategy by incorporating PD-1-directed targeting and IL-2 activity associated with IL-2Rα engagement.
According to PharmaEssentia, preclinical characterization showed that PEC3001 selectively enhanced antitumor T-cell activity while minimizing systemic immune activation. The company also reported a favorable preclinical safety profile, supporting further development toward first-in-human clinical studies.
These findings are relevant to the broader effort to develop immunotherapies that stimulate antitumor responses without producing excessive activation throughout the immune system.
Nevertheless, preclinical safety findings do not establish that a candidate will be safe or well tolerated in humans. Clinical studies will be needed to determine the appropriate dose, characterize potential adverse effects, and assess whether the targeted mechanism produces meaningful biological and clinical activity in patients.
Addressing the Challenges of Cytokine-Based Therapies
Cytokine-based immunotherapies have attracted interest because they can influence several aspects of immune function. IL-2, in particular, can support the activity and expansion of T cells, which play a central role in recognizing and eliminating cancer cells.
At the same time, broad cytokine stimulation can affect multiple immune cell populations and may produce unwanted systemic effects. Researchers are therefore investigating approaches that modify cytokine activity, improve targeting, or influence receptor engagement to achieve a more controlled immune response.
PEC3001 is intended to address these challenges through its PD-1-targeted design and IL-2Rα-active mechanism.
By linking targeting and cytokine activity within one investigational biologic, the candidate aims to concentrate its effects on relevant immune cell populations. PharmaEssentia’s reported preclinical results suggest that this strategy may enhance antitumor T-cell activity while limiting systemic immune activation.
Further research will be important to establish how selectively PEC3001 acts, how its effects vary across different biological settings, and whether its proposed advantages can be maintained during clinical development.
The planned progression toward first-in-human studies would represent a significant next step for the program. Before clinical testing can begin, the candidate will need to undergo the necessary investigational new drug (IND)-enabling work and satisfy applicable regulatory requirements.
If supported by subsequent research, PEC3001 could contribute to the development of targeted cytokine-based approaches for solid tumors. Its eventual therapeutic role, however, will depend on clinical evidence regarding safety, pharmacological activity, and efficacy.
PharmaEssentia Expands Its Research Beyond MPNs
The two poster presentations reflect PharmaEssentia’s broader strategy to build a diversified biologics pipeline that retains myeloproliferative neoplasms as a core focus while pursuing additional opportunities in oncology.
MPNs are a group of hematologic disorders characterized by abnormal production of blood cells in the bone marrow. PharmaEssentia has developed expertise in biologic medicines and cytokine-related technologies relevant to hematology, providing a scientific foundation for its wider research activities.
The company is now applying capabilities in PEGylated cytokines, checkpoint receptor biology, and cytokine engineering to investigate new approaches to solid tumor treatment.
These areas of expertise offer complementary opportunities for drug discovery. PEGylation can be used to modify the properties of therapeutic molecules, while cytokine engineering seeks to adjust the activity and behavior of immune-signaling proteins. Checkpoint receptor research, meanwhile, focuses on understanding and modulating the pathways that regulate immune cell function.
The PEC2001 and PEC3001 programs apply different elements of this scientific foundation to distinct therapeutic strategies. PEC2001 is designed to influence myeloid immune regulation through dual receptor antagonism, whereas PEC3001 combines checkpoint targeting with cytokine-mediated T-cell stimulation.
Although both programs remain in preclinical development, their presentation at SITC provides an opportunity to communicate the underlying research and emerging findings to the scientific and oncology communities.
The company has indicated that it intends to advance its solid tumor candidates into IND-enabling studies and Phase 1 clinical development. Progression will depend on the results of additional research, completion of the required development activities, and the relevant regulatory processes.
SITC 2026 Provides a Platform for Scientific Exchange
The SITC 41st Annual Meeting, scheduled for November 4–8, 2026, in Phoenix, Arizona, will provide a forum for researchers and industry participants to discuss advances in cancer immunotherapy.
The meeting brings attention to emerging therapeutic strategies, immune mechanisms, and research findings that may inform future oncology drug development.
PharmaEssentia’s two presentations will contribute preclinical findings from its internal R&D portfolio, highlighting efforts to address immune suppression and improve targeted immune activation in solid tumors.
The PEC2001 poster will focus on the potential of dual LILRB1/LILRB2 inhibition to reprogram myeloid immunity and enhance antitumor activity. The PEC3001 presentation will examine the combination of PD-1 targeting and IL-2Rα-active cytokine activity, with an emphasis on T-cell activation and the potential to limit systemic immune stimulation.
Both programs remain investigational, and the reported findings do not establish safety or effectiveness in humans. However, they illustrate the company’s strategy of applying its biologics research capabilities to multiple mechanisms in cancer immunotherapy.
As PharmaEssentia works toward the next stages of development, further preclinical characterization and planned IND-enabling activities will help determine whether these candidates are ready to enter clinical testing.
The presentations mark a research milestone for the company as it seeks to expand its oncology pipeline beyond MPNs. The next phase will focus on generating additional evidence and preparing the candidates for potential first-in-human evaluation, with the long-term objective of developing new biologic treatment options for patients with cancer.
About PharmaEssentia
PharmaEssentia Corporation, headquartered in Taipei, Taiwan, is a global and rapidly growing biopharmaceutical innovator. Leveraging deep expertise and proven scientific principles, PharmaEssentia aims to deliver effective new biologics for challenging diseases in the areas of hematology, oncology, and immunology with one approved product and a diversifying pipeline.
Founded in 2003 by a team of Taiwanese-American executives and renowned scientists from U.S. biotechnology and pharmaceutical companies, today PharmaEssentia is expanding its global presence with operations in the U.S., Japan, China, and Korea, along with a world-class biologics production facility in Taichung, Taiwan. For more information about PharmaEssentia, visit the website or LinkedIn.